B-cell translocation gene 3 (BTG3) has been identified as a candidate driver gene for various cancers, but its specific role in colorectal cancer (CRC) is poorly understood. We aimed to investigate the relationship between expression of BTG3 and clinicopathological features and prognosis, as well as to explore the effects and the role of a possible BTG3 molecular mechanism on aggressive colorectal cancer behavior.
BTG3 expression was assessed by immunohistochemistry (IHC) on specimens from 140 patients with CRC. The association of BTG3 expression with clinicopathological features was examined. To confirm the biological role of BTG3 in CRC, two CRC cell lines expressing BTG3 were used and BTG3 expression was knocked down by shRNA. CCK-8, cell cycle, apoptosis, migration, and invasion assays were performed. The influence of BTG3 knockdown was further investigated by genomic microarray to uncover the potential molecular mechanisms underlying BTG3-mediated CRC development and progression.
BTG3 was downregulated in colorectal cancer tissues and positively correlated with pathological classification (p = 0.037), depth of invasion (p = 0.016), distant metastasis (p = 0.024), TNM stage (p = 0.007), and overall survival (OS) and disease-free survival (DFS). BTG3 knockdown promoted cell proliferation, migration, invasion, relieved G2 arrest, and inhibited apoptosis in HCT116 and LoVo cells. A genomic microarray analysis showed that numerous tumor-associated signaling pathways and oncogenes were altered by BTG3 knockdown. At the mRNA level, nine genes referred to the extracellular-regulated kinase/mitogen-activated protein kinase pathway were differentially expressed. Western blotting revealed that BTG3 knockdown upregulated PAK2, RPS6KA5, YWHAB, and signal transducer and activator of transcription (STAT)3 protein levels, but downregulated RAP1A, DUSP6, and STAT1 protein expression, which was consistent with the genomic microarray data.
BTG3 expression might contribute to CRC carcinogenesis. BTG3 knockdown might strengthen the aggressive colorectal cancer behavior.
Alefan Q, Malhees R, Mhaidat N (2017) Direct medical cost associated with colorectal cancer in north of Jordan. Curr Probl Cancer. https://doi.org/10.1016/j.currproblcancer.2017.05.001 PubMed
Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ (2009) Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 125(10):2332–2341. https://doi.org/10.1002/ijc.24604 CrossRefPubMed
Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S et al (2012) Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One 7(12):e51862. https://doi.org/10.1371/journal.pone.0051862 CrossRefPubMedPubMedCentral
Chen X, Chen G, Cao X, Zhou Y, Yang T, Wei S (2013) Downregulation of BTG3 in non-small cell lung cancer. Biochem Biophys Res Commun 437(1):173–178. https://doi.org/10.1016/j.bbrc.2013.06.062 CrossRefPubMed
Clark CJ, McDade DM, O’Shaughnessy CT, Morris BJ (2007) Contrasting roles of neuronal Msk1 and Rsk2 in Bad phosphorylation and feedback regulation of Erk signalling. J Neurochem 102(4):1024–1034. https://doi.org/10.1111/j.1471-4159.2007.04601.x CrossRefPubMed
Davie JR, Spencer VA (2001) Signal transduction pathways and the modification of chromatin structure. Prog Nucleic Acid Res Mol Biol 65:299–340 PubMed
Dong YC, Han QL, Zou Y, Deng ZL, Lu XL, Wang XH et al (2012) Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells. Mol Cell Biochem 370(1–2):89–102. https://doi.org/10.1007/s11010-012-1401-0 CrossRefPubMed
Hough C, Radu M, Dore JJ (2012) Tgf-beta induced Erk phosphorylation of smad linker region regulates smad signaling. PLoS One 7(8):e42513. https://doi.org/10.1371/journal.pone.0042513 CrossRefPubMedPubMedCentral
Huang D, Ding Y, Luo WM, Bender S, Qian CN, Kort E et al (2008) Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Can Res 68(1):81–88. https://doi.org/10.1158/0008-5472.can-07-5311 CrossRef
Ju H, Li X, Li H, Wang X, Wang H, Li Y et al (2013) Mediation of multiple pathways regulating cell proliferation, migration, and apoptosis in the human malignant glioma cell line U87MG via unphosphorylated STAT1: laboratory investigation. J Neurosurg 118(6):1239–1247. https://doi.org/10.3171/2013.3.JNS122051 CrossRefPubMed
Lai KC, Huang AC, Hsu SC, Kuo CL, Yang JS, Wu SH et al (2010) Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem 58(5):2935–2942. https://doi.org/10.1021/jf9036694 CrossRefPubMed
Li X, Wen W, Liu K, Zhu F, Malakhova M, Peng C et al (2011) Phosphorylation of caspase-7 by p21-activated protein kinase (PAK) 2 inhibits chemotherapeutic drug-induced apoptosis of breast cancer cell lines. J Biol Chem 286(25):22291–22299. https://doi.org/10.1074/jbc.M111.236596 CrossRefPubMedPubMedCentral
Lv Z, Zou H, Peng K, Wang J, Ding Y, Li Y et al (2013) The suppressive role and aberrent promoter methylation of BTG3 in the progression of hepatocellular carcinoma. PLoS One 8(10):e77473. https://doi.org/10.1371/journal.pone.0077473 CrossRefPubMedPubMedCentral
Majid S, Dar AA, Shahryari V, Hirata H, Ahmad A, Saini S et al (2010) Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer. Cancer 116(1):66–76. https://doi.org/10.1002/cncr.24662 PubMedPubMedCentral
Sakamoto KM, Frank DA (2009) CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res 15(8):2583–2587. https://doi.org/10.1158/1078-0432.CCR-08-1137 CrossRefPubMedPubMedCentral
Sofroniew MV, Howe CL, Mobley WC (2001) Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24:1217–1281. https://doi.org/10.1146/annurev.neuro.24.1.1217 CrossRefPubMed
Tkach M, Rosemblit C, Rivas MA, Proietti CJ, Diaz Flaque MC, Mercogliano MF et al (2013) p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth. Endocr Relat Cancer 20(2):197–212. https://doi.org/10.1530/ERC-12-0194 CrossRefPubMed
Varghese C, Shin HR (2014) Strengthening cancer control in China. Lancet Oncol 15(5):484–485. https://doi.org/10.1016/S1470-2045(14)70056-7 CrossRefPubMed
Weng CJ, Chau CF, Hsieh YS, Yang SF, Yen GC (2008) Lucidenic acid inhibits PMA-induced invasion of human hepatoma cells through inactivating MAPK/ERK signal transduction pathway and reducing binding activities of NF-kappaB and AP-1. Carcinogenesis 29(1):147–56. https://doi.org/10.1093/carcin/bgm261 CrossRefPubMed
Yu J, Zhang Y, Qi Z, Kurtycz D, Vacano G, Patterson D (2008). Methylation-mediated downregulation of the B-cell translocation gene 3 (BTG3) in breast cancer cells. Gene Expr 14(3):173–82 PubMed
Yuan ZL, Guan YJ, Wang L, Wei W, Kane AB, Chin YE (2004) Central role of the threonine residue within the p + 1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. Mol Cell Biol 24(21):9390–400. https://doi.org/10.1128/MCB.24.21.9390-9400.2004 CrossRefPubMedPubMedCentral
Zeng QH, Li SL, Chepeha DB, Giordano TJ, Li J, Zhang HL et al (2005) Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 8(1):13–23. https://doi.org/10.1016/j.ccr.2005.06.004 CrossRefPubMed
- The function of BTG3 in colorectal cancer cells and its possible signaling pathway
- Springer Berlin Heidelberg
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II